Ouyang Jun, Wu Deping, Gan Yumei, Tang Yuming, Wang Hui, Huang Jiangnan
Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing, Jiangsu, China.
Cell Death Dis. 2025 Mar 18;16(1):183. doi: 10.1038/s41419-025-07525-z.
Cardiovascular diseases are the leading causes of death worldwide. However, there are still shortcomings in the currently employed treatment methods for these diseases. Therefore, exploring the molecular mechanisms underlying cardiovascular diseases is an important avenue for developing new treatment strategies. Previous studies have confirmed that metabolic and epigenetic alterations are often involved in cardiovascular diseases across patients. Moreover, metabolic and epigenetic factors interact with each other and affect the progression of cardiovascular diseases in a coordinated manner. Lactylation is a novel posttranslational modification (PTM) that links metabolism with epigenetics and affects disease progression. Therefore, analyzing the crosstalk between cellular metabolic and epigenetic factors in cardiovascular diseases is expected to provide insights for the development of new treatment strategies. The purpose of this review is to describe the relationship between metabolic and epigenetic factors in heart development and cardiovascular diseases such as heart failure, myocardial infarction, and atherosclerosis, with a focus on acylation and methylation, and to propose potential therapeutic measures.
心血管疾病是全球主要的死亡原因。然而，目前用于治疗这些疾病的方法仍存在不足。因此，探索心血管疾病的分子机制是开发新治疗策略的重要途径。先前的研究证实，代谢和表观遗传改变在心血管疾病患者中经常出现。此外，代谢和表观遗传因素相互作用，并以协调的方式影响心血管疾病的进展。乳酰化是一种新的翻译后修饰（PTM），它将代谢与表观遗传学联系起来，并影响疾病进展。因此，分析心血管疾病中细胞代谢和表观遗传因素之间的相互作用有望为新治疗策略的开发提供思路。本综述的目的是描述代谢和表观遗传因素在心脏发育和心血管疾病（如心力衰竭、心肌梗死和动脉粥样硬化）中的关系，重点关注酰化和甲基化，并提出潜在的治疗措施。
Zotero 插件
